BiotechTube
axelyf

axelyf

Copenhagen, Europe - Other· Est.
axelyf.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Axelyf is a private, preclinical-stage biotech leveraging its proprietary AXL lipid nanoparticle platform and ANNA™ AI model to develop next-generation RNA therapeutics. Its lead programs target significant unmet needs in solid tumors (AX-004, an in vivo CAR-T) and autoimmune hepatitis (AX-003). The company operates a dual strategy of building its own asset pipeline and licensing its tunable LNP technology to partners, positioning itself at the intersection of advanced drug delivery and AI-driven design.

OncologyAutoimmune Diseases

Technology Platform

The AXL platform is a next-generation, tunable lipid nanoparticle (LNP) system engineered for precise tissue-selective delivery of RNA payloads. It is optimized and accelerated by ANNA™, a proprietary AI model for lipid design that learns from fragmented real-world data.

Opportunities

The massive unmet need in solid tumor CAR-T therapy and autoimmune diseases presents a multi-billion dollar market for successful assets.
Additionally, the booming field of RNA therapeutics creates a high demand for best-in-class, tunable delivery platforms like AXL, enabling lucrative partnership and licensing deals.

Risk Factors

High technical risk in translating novel in vivo CAR-T and liver-targeting approaches from compelling preclinical data to safe and effective human therapies.
Intense competition in the RNA delivery space from larger, well-funded entities poses significant commercial and platform adoption challenges.

Competitive Landscape

Axelyf competes in the crowded next-generation LNP space against companies like ReCode Therapeutics, Acuitas Therapeutics, and large pharma internal efforts. Its differentiation lies in its AI-driven design (ANNA™) and preclinical data showing tissue-tunable delivery and superiority over benchmark LNPs in NHPs.

More companies in Europe - Other →